## For the EORTC Head and Neck Cooperative Group A total of 185 eligible patients with advanced inoperable squamous cell carcinoma of the head and neck were randomized into two groups; the cisplatin, methotrexate, bleomycin, and vincristine (CABO) group received cisplatin (50 mg/m2; day 4), methot
Methyl-ccnu, alone and in combination with vincristine, or vincristine and methotrexate, in advanced bronchogenic carcinoma
β Scribed by Frederick Richards; M. Robert Cooper; Hyman B. Muss; Douglas R. White; Charles L. Spurr
- Publisher
- John Wiley and Sons
- Year
- 1976
- Tongue
- English
- Weight
- 415 KB
- Volume
- 38
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
BACKGROUND. L-asparaginase in combination with methotrexate has synergistic antileukemic activity in a schedule-dependent fashion. A new preparation of L-asparaginase, polyethylene-glycol conjugated (PEG)-asparaginase, is a pharmacologically different formulation of L-asparaginase with distinct prop
## Background: This study was undertaken to determine whether the use of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin as first-line therapy increases the proportion of major responders and overall survival in patients with unresectable or metastatic tra